Distinct Regulation of EZH2 and its Repressive H3K27me3 Mark in Polyomavirus-Positive and -Negative Merkel Cell Carcinoma.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
10 2023
Historique:
received: 28 06 2022
revised: 15 02 2023
accepted: 17 02 2023
medline: 25 9 2023
pubmed: 11 4 2023
entrez: 10 4 2023
Statut: ppublish

Résumé

Merkel cell carcinoma (MCC) is an aggressive skin cancer for which Merkel cell polyomavirus integration and expression of viral oncogenes small T and Large T have been identified as major oncogenic determinants. Recently, a component of the PRC2 complex, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) that induces H3K27 trimethylation as a repressive mark has been proposed as a potential therapeutic target in MCC. Because divergent results have been reported for the levels of EZH2 and trimethylation of lysine 27 on histone 3, we analyzed these factors in a large MCC cohort to identify the molecular determinants of EZH2 activity in MCC and to establish MCC cell lines' sensitivity to EZH2 inhibitors. Immunohistochemical expression of EZH2 was observed in 92% of MCC tumors (156 of 170), with higher expression levels in virus-positive than virus-negative tumors (P = 0.026). For the latter, we showed overexpression of EZHIP, a negative regulator of the PRC2 complex. In vitro, ectopic expression of the large T antigen in fibroblasts led to the induction of EZH2 expression, whereas the knockdown of T antigens in MCC cell lines resulted in decreased EZH2 expression. EZH2 inhibition led to selective cytotoxicity on virus-positive MCC cell lines. This study highlights the distinct mechanisms of EZH2 induction between virus-negative and -positive MCC.

Identifiants

pubmed: 37037414
pii: S0022-202X(23)01973-5
doi: 10.1016/j.jid.2023.02.038
pii:
doi:

Substances chimiques

Histones 0
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43
Antigens, Viral, Tumor 0
EZH2 protein, human EC 2.1.1.43

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1937-1946.e7

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Marie-Alice Durand (MA)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France.

Aurélie Drouin (A)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France.

Alice Mouchard (A)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France; Department of Dermatology, CHRU of Tours, University of Tours, Chambray-lès-Tours, France.

Laurine Durand (L)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France.

Clara Esnault (C)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France.

Patricia Berthon (P)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France.

Anne Tallet (A)

Platform of Somatic Tumor Molecular Genetics, CHU of Tours, University of Tours, Tours, France.

Yannick Le Corre (Y)

Dermatology Department, CHU of Angers, LUNAM University, Angers, France.

Ewa Hainaut-Wierzbicka (E)

Dermatology Department, CHU of Poitiers, University of Poitiers, Poitiers, France.

Astrid Blom (A)

Department of General and Oncologic Dermatology, Ambroise-Paré Hospital, CARADERM Network, Boulogne-Billancourt, France; Research unit EA 4340, University of Versailles-Saint-Quentin-en-Yvelines, Paris-Saclay University, Boulogne-Billancourt, France.

Philippe Saiag (P)

Department of General and Oncologic Dermatology, Ambroise-Paré Hospital, CARADERM Network, Boulogne-Billancourt, France; Research unit EA 4340, University of Versailles-Saint-Quentin-en-Yvelines, Paris-Saclay University, Boulogne-Billancourt, France.

Nathalie Beneton (N)

Dermatology Department, CHU of Le Mans, University of Le Mans, Le Mans, France.

Guido Bens (G)

Dermatology department, CHR Orleans, Orleans, France.

Charlee Nardin (C)

Dermatology, CHU Besançon, Besançon, France; INSERM 1098, Université Bourgogne Franche-Comté, Besançon, France.

François Aubin (F)

Dermatology, CHU Besançon, Besançon, France; INSERM 1098, Université Bourgogne Franche-Comté, Besançon, France.

Monica Dinulescu (M)

Dermatology department, CHU Rennes, Institut Dermatologique du Grand Ouest (IDGO), Rennes, France.

Christine Collin (C)

Platform of Somatic Tumor Molecular Genetics, CHU of Tours, University of Tours, Tours, France.

Gaëlle Fromont-Hankard (G)

Pathology Department, CHU of Tours, University of Tours, Tours, France.

Bernard Cribier (B)

Dermatology Department, CHU of Strasbourg, University of Strasbourg, Strasbourg, France.

Sara Laurent-Roussel (S)

Paris - La roquette, National Dermatopathology Center, Paris, France.

Kristof Cokelaere (K)

Pathology Department, Regional Hospital Jan Yperman, Ieper, Belgium.

Roland Houben (R)

Department of Dermatology, Venerology and Allergology, University Hospital of Würzburg, Würzburg, Germany.

David Schrama (D)

Department of Dermatology, Venerology and Allergology, University Hospital of Würzburg, Würzburg, Germany.

Paul Peixoto (P)

INSERM, EFS-BFC, UMR 1098 RIGHT, University Bourgogne-Franche-Comté, Besançon, France; EPIgenetics and GENe Expression Technical Platform (EPIGENExp), University Bourgogne Franche-Comté, Besançon, France.

Eric Hervouet (E)

INSERM, EFS-BFC, UMR 1098 RIGHT, University Bourgogne-Franche-Comté, Besançon, France; EPIgenetics and GENe Expression Technical Platform (EPIGENExp), University Bourgogne Franche-Comté, Besançon, France.

Kamel Bachiri (K)

Department of Biology, Inserm U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse-PRISM, CHU Lille, Université de Lille, Lille, France.

Diala Kantar (D)

Department of Biology, Inserm U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse-PRISM, CHU Lille, Université de Lille, Lille, France.

Etienne Coyaud (E)

Department of Biology, Inserm U1192, Protéomique Réponse Inflammatoire Spectrométrie de Masse-PRISM, CHU Lille, Université de Lille, Lille, France.

Serge Guyétant (S)

Pathology Department, CHU of Tours, University of Tours, Tours, France; Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France.

Mahtab Samimi (M)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France; Department of Dermatology, CHRU of Tours, University of Tours, Chambray-lès-Tours, France.

Antoine Touzé (A)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France.

Thibault Kervarrec (T)

Team "Biologie des Infections à Polyomavirus", ISP UMR 1282, INRAE, University of Tours, Tours, France; Pathology Department, CHU of Tours, University of Tours, Tours, France. Electronic address: thibaultkervarrec@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH